Clinical Interests for Referring Providers
My main clinical interest is in the evaluation, diagnosis and treatment of patients with non-epileptic seizures.
Research Interest for Referring Providers
CURRENT RESEARCH SUPPORT
5/28/14-Closed
Principal Investigator
USL P261-408: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizure Clusters
Direct cost per patient: $11,698
Length of Study: Until the drug is approved
11/15/2012-Closed
Principal Investigator
USL P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters
Direct cost per patient: $9445
Length of study: Until drug is approved
1/02/14-2015
Principal Investigator
Marinus 1042-0603: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment
Direct cost per patient: $9950
Length of study: 9 months
11/19/13-2016
Principal Investigator
UCB Biosciences 1379: An Open-Label, Multicenter, Follow-Up Study to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy
Direct Cost per patient: $11,939
7/09/2013-2016
Principal Investigator
UCB Biosciences 1358: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of Brivaracetam in subjects with partial onset seizures
Direct Cost per patient: $11,939
1/1/12-Closed
Principal Investigator
USL P261-401: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1
Direct cost per patient: $9445
Length of study: 6 months, dependent upon first seizure cluster after randomization
3/03/11 – 6/27/12
Principal Investigator
UCB SP0962 study: An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy
Direct costs: $6337 (per patient for entire study)
Enrollment: 1 patient
Length of study: 56 weeks
7/07/11-2016
Principal Investigator
Sunovion BIA-2093-304 study: Efficacy and safety of eslicarbazabine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled parallel-group, multicenter clinical trial
Direct costs: $14344 (per patient for entire study)
Enrollment: 3 patients
Length of study: 41 months
3/03/11 – 01/10/12
Principal Investigator
UCB SP0961, An open-label pilot study to assess the safety of oral lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy
Direct costs: $7878 (per patient for entire study)
Enrollment: 3 patients
Length of study: 24 months
11/30/09 – 2016
Principal Investigator
Sunovion, 093-050 study; Long-Term Eslicarbazepine Acetate Extension Study
Direct costs: $7314 (per patient for entire study)
Enrollment: 2 patients at $7314 each = $14,628
Length of study: 36 mos.
12/23/09 – 05/17/12
Principal Investigator
Supernus Prosper 302 study: Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications
Direct costs: $5270 (per patient for entire study)
Indirect costs: $1370
Enrollment: 4 patients at $5270 each = $21,080
Length of study: 14 mos.
12/10/09 – 10/14/11
Principal Investigator
Supernus Prosper 301 study: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Three Concomitant Antiepileptic Medications
Direct costs: $8620 (per patient for entire study)
Indirect costs: $2241
Enrollment: 4 patients at $8620 each = $34,480
Length of study: 8-9 mos.
11/06/09 – 08/29/13
Principal Investigator
Sunovion 093-045 study: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Direct costs: $12030 (per patient for entire study)
Indirect costs: $3027
Enrollment: 3 patients at $12030 each = $36,090
Length of study: 2 yrs.
01/31/08 – 01/15/10
Principal Investigator
Marinus Pharmaceuticals, Inc, Research 1042-0601 study; an open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures.
01/31/08 – 02/25/09
Principal Investigator
Marinus Pharmaceuticals, Inc, Research 1042-0600 study; A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.
Clinic Phone: (720) 848-2080
CV
CV Strom_01_2023.doc